MARKETS / NASDAQ / PBYI

NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP

Puma Biotechnology, Inc. PBYI

15 fiscal years on record · USD · FY2025 reported · SEC filings only

Revenue

$228.4M

▼ 0.9% YoY

Net income

$31.1M

▲ 2.8% YoY

Free cash flow

$41.7M

▲ 7.4% YoY

In brief

What this company does

Puma Biotechnology, Inc. develops and commercializes products for cancer care and treatment. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. It has in-licensed, and is responsible for the global development and commercialization of, alisertib, a selective, small-molecule inhibitor of Aurora Kinase A. In the United States, it sells its products through a specialty pharmacy network consisting of Accredo, CVS, ONCO 360, Optum and Biologics, and a specialty distributor network consisting of McKesson, ASD/Oncology Supply, Cardinal Health, DMS Pharmaceutical Group and Bio Care. As of December 31, 2025, its workforce consisted of 179 full-time employees. It was originally incorporated in the State of Delaware in April 2007 under the name Innovative Acquisitions Corp. In October 2011, it acquired Puma Biotechnology, Inc., a privately held Delaware corporation formed on September 15, 2010, which became its wholly owned subsidiary, subsequently merged with and into it, and it changed its name to Puma Biotechnology, Inc.

Written from the business description in PUMA BIOTECHNOLOGY, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth

USD 228.4M

Revenue, FY2025 · full 15-year series below

Revenue $M Net income $M

FY2025 · Revenue 228.4 · Net income 31.1

Compound annual growth

Revenue

+0.0%

+0.3%

Net income

+2396.3%

3 yrs

5 yrs

10 yrs

15 yrs

Revenue compounded at +0.3% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

14 cents

of every revenue dollar became profit

Operating margin Net margin

FY2025 · Operating 16.3% · Net 13.6%

ROE

FY2025 · ROE 28.0%

Gross margin74.5%

Operating margin16.3%

Net margin13.6%

Return on assets14.5%

EBITDAUSD 37.7M

Each USD of equity produced 28 cents of profit this year.

Cash & shareholders

—

returned in FY2025 · dividends + net buybacks

Free cash flow $M

FY2025 · FCF 41.7

Total assetsUSD 216.3M

EquityUSD 130.3M

CashUSD 29.6M

Gross debtUSD 22.5M

Net debtUSD -7.1M

Current ratio2.00×

The company holds more cash than debt.

The 15-year record

15 fiscal years

Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue $B	0.2	0.2	0.2	0.2	0.3	0.2	0.3	0.3	0.0	·	·	·	·	·	·
Operating income $B	0.0	0.0	0.0	0.0	0.0	−0.0	−0.0	−0.1	−0.3	−0.3	−0.2	−0.1	−0.1	−0.1	−0.0
EBITDA $B	0.0	0.0	0.0	0.0	0.0	−0.0	−0.0	−0.1	−0.3	·	·	·	·	·	·
Income tax $B	0.0	−0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	·
Net income $B	0.0	0.0	0.0	0.0	−0.0	−0.1	−0.1	−0.1	−0.3	−0.3	−0.2	−0.1	−0.1	−0.1	−0.0
Free cash flow $B	0.0	0.0	0.0	−0.0	0.0	0.0	0.0	−0.0	−0.2	−0.1	−0.2	−0.1	−0.1	·	−0.0
EPS, diluted $	0.61	0.62	0.45	0.00	−0.72	−1.52	−1.95	−2.99	−7.85	−8.29	−7.45	−4.73	−1.90	−3.42	−1.32
Dividend / sh $	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·
Payout %	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·
ROE %	28.0	41.6	57.5	0.0	·	−1042.3	−292.0	−259.3	−221.9	−132.8	−148.1	−141.2	−51.3	−81.1	−18.8
Shares out B	0.05	0.05	0.05	0.05	0.04	0.04	0.04	0.04	0.04	0.04	0.03	0.03	0.03	0.03	0.02

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance

Company facts, as filed

How we verify · 1 failures in 60 reconciliationsAUDITED

Reconciled in 15 of 19 fiscal years. 26 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures

ActivityPharmaceutical Preparations

Listed onNASDAQ

Incorporated inDelaware

Fiscal year endsDecember 31

SEC categorysmaller reporting company

Data on record since2010